Cargando…
Long term use of bevacizumab in the treatment of triple negative breast cancer with giant tumor in chest wall: A case report
RATIONALE: Triple-negative breast cancer (TNBC) is associated with unfavorable prognosis due to lack of targeted agents. Bevacizumab, an anti-angiogenic monoclonal antibody against vascular endothelial growth factor A, has shown clinical effects in patients with TNBC. PATIENT CONCERNS: We reported a...
Autores principales: | Gui, Xinyu, Li, Huiping, Song, Guohong, Shao, Bin, Jiang, Hanfang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283199/ https://www.ncbi.nlm.nih.gov/pubmed/30508942 http://dx.doi.org/10.1097/MD.0000000000013410 |
Ejemplares similares
-
Multicenter phase II study of apatinib single or combination therapy in HER2-negative breast cancer involving chest wall metastasis
por: Li, Huiping, et al.
Publicado: (2021) -
Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple‐negative breast cancer cohort
por: Liu, Xiaoran, et al.
Publicado: (2017) -
Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing
por: Wang, Nan, et al.
Publicado: (2020) -
Pegylated liposomal doxorubicin (Duomeisu(®)) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study
por: Jiang, Hanfang, et al.
Publicado: (2023) -
Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting
por: Zhang, Ruyan, et al.
Publicado: (2023)